Prostate Cancer Group Archives

Dr Nicolás Anselmino receives a PCF Young Investigator Award to advance personalized medicine in prostate cancer

Nicolás Anselmino, a postdoctoral researcher in the Prostate Cancer Group at the Vall d’Hebron Institute of Oncology (VHIO), has received…

VHIO presents new advances at ASCO consolidating precision medicine in metastatic prostate cancer

Results from the phase 3 TALAPRO-3 trial show that the combination of enzalutamide and talazoparib reduces the risk of progression…

A study led by SOLTI and VHIO facilitates nationwide access to genomic testing across Spain for patients with metastatic prostate cancer and redefines therapeutic strategy in more than half of cases

The HOPE Prostate (SOLTI-2102) study analyzed 208 samples (116 tissue and 92 liquid biopsies) from 146 patients with metastatic prostate…

Novel drug combination significantly improves survival in subgroup of patients with metastatic castration-resistant prostate cancer

Published in The Lancet, final overall survival results of the phase 3 TALAPRO-2 trial show that talazoparib plus enzalutamide significantly…

Novel drug combination shows promise in metastatic castration-resistant prostate cancer

The phase 3, multi-center, open-label, randomized CONTACT-02 trial, directed by Neeraj Agarwal of the Huntsman Cancer Institute at the University…

Presented at ASCO GU 2025, results of the phase 3 TALAPRO-2 trial support a new standard-of-care for metastatic castration-resistant prostate cancer

Results of the multi-center, international phase 3 TALAPRO-2 trial show that the combination of PARP inhibitor talazoparib plus anti-androgen enzalutamide…

RAD51 biomarker could complement next-generation sequencing in personalizing prostate cancer treatment

Published in Cell Reports Medicine*, results of a VHIO-led study support the feasibility of using RAD51 testing to complement next-generation…